(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 1.41% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Teva Pharmaceutical Industries's revenue in 2025 is $16,628,000,000.On average, 6 Wall Street analysts forecast TEVA's revenue for 2025 to be $19,365,715,388,805, with the lowest TEVA revenue forecast at $19,244,603,783,592, and the highest TEVA revenue forecast at $19,561,469,809,886. On average, 6 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,441,885,062,543, with the lowest TEVA revenue forecast at $19,322,610,045,948, and the highest TEVA revenue forecast at $19,636,539,365,894.
In 2027, TEVA is forecast to generate $19,983,274,907,765 in revenue, with the lowest revenue forecast at $19,694,252,528,528 and the highest revenue forecast at $20,306,980,247,826.